Literature DB >> 19541490

Synthesis and biological evaluation of SANT-2 and analogues as inhibitors of the hedgehog signaling pathway.

Anita Büttner1, Katrin Seifert, Thomas Cottin, Vasiliki Sarli, Lito Tzagkaroulaki, Stefan Scholz, Athanassios Giannis.   

Abstract

Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. In vertebrates, the hh gene encodes three different unique proteins: sonic hedgehog (Shh), desert hedgehog (Dhh) and indian hedgehog (Ihh). Disruption of the Hh signaling pathway leads to severe disorders in the development of vertebrates whereas aberrant activation of the Hh pathway has been associated with several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers. In vivo evidence suggests the antagonism of excessive Hh signaling provides a route to unique mechanism-based anti-cancer therapies. Recently the small molecule SANT-2 was identified as a potent antagonist of Hh-signaling pathway. Here, we describe the synthesis, SAR studies as well as biological evaluation of SANT-2 and its analogues. Fifteen SANT-2 derivatives were synthesized and analyzed for their interference with the expression of the Hh target gene Gli1 in a reporter gene assay. By comparison of structure and activity important molecular descriptors for Gli inhibition could be identified. Furthermore we identified derivative TC-132 that was slightly more potent than the parent compound SANT-2. Selected compounds were tested for Hh related teratogenic effects in the small teleost model medaka. Albeit Gli expression has indicated a 16-fold higher Hh-inhibiting activity than observed for the plant alkaloid cyclopamine, none of the tested compounds were able to induce the cyclopamine-specific phenotype in the medaka assay.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541490     DOI: 10.1016/j.bmc.2009.06.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Wnt and SHH in prostate cancer: trouble mongers occupy the TRAIL towards apoptosis.

Authors:  A A Farooqi; S Mukhtar; A M Riaz; S Waseem; S Minhaj; B A Dilawar; B A Malik; A Nawaz; S Bhatti
Journal:  Cell Prolif       Date:  2011-10-04       Impact factor: 6.831

Review 2.  Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 3.  Novel investigational drugs for basal cell carcinoma.

Authors:  Po-Lin So; Jean Y Tang; Ervin H Epstein
Journal:  Expert Opin Investig Drugs       Date:  2010-09       Impact factor: 6.206

4.  Small molecule inhibitors of Smoothened ciliary localization and ciliogenesis.

Authors:  Victoria M Wu; Steven C Chen; Michelle R Arkin; Jeremy F Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-03       Impact factor: 11.205

5.  Synthesis and characterization of Sant-75 derivatives as Hedgehog-pathway inhibitors.

Authors:  Chao Che; Song Li; Bo Yang; Shengchang Xin; Zhixiong Yu; Taofeng Shao; Chuanye Tao; Shuo Lin; Zhen Yang
Journal:  Beilstein J Org Chem       Date:  2012-06-06       Impact factor: 2.883

6.  Synthesis of 2-methoxybenzamide derivatives and evaluation of their hedgehog signaling pathway inhibition.

Authors:  Chiyu Sun; Dajun Zhang; Tian Luan; Youbing Wang; Wenhu Zhang; Lin Lin; Meihua Jiang; Ziqian Hao; Ying Wang
Journal:  RSC Adv       Date:  2021-06-28       Impact factor: 3.361

7.  Novel small molecules targeting ciliary transport of Smoothened and oncogenic Hedgehog pathway activation.

Authors:  Bomi Jung; Ana C Messias; Kenji Schorpp; Arie Geerlof; Günter Schneider; Dieter Saur; Kamyar Hadian; Michael Sattler; Erich E Wanker; Stefan Hasenöder; Heiko Lickert
Journal:  Sci Rep       Date:  2016-03-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.